Viking Therapeutics Inc said on Tuesday its experimental drug met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease, sending its shares about 6% higher in early trade.
Posts
Akero Therapeutics Inc. said on Tuesday its lead experimental drug met the main goal for treatment of a type of fatty liver disease, sending the company’s shares soaring more than 60% in premarket trading.
